vatalanib has been researched along with Adenocarcinoma, Basal Cell in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Bajetta, E; Berg, W; Chen, BL; Germond, C; Hecht, JR; Jalava, T; Köhne, CH; Laurent, D; Lebwohl, D; Lin, E; Meinhardt, G; Moore, M; Valle, J; Van Cutsem, E | 1 |
| Berg, W; Bodoky, G; Chen, BL; Hainsworth, JD; Hecht, JR; Jäger, E; Jalava, T; Kerr, D; Laurent, D; Lebwohl, D; Lloyd-Salvant, K; Major, P; Meinhardt, G; Pendergrass, K; Trarbach, T; Wolff, RA | 1 |
| Brasch, RC; Carter, WO; Floyd, E; Fu, Y; Novikov, V; Preda, A; Roberts, TP; Shames, DM; Turetschek, K; Wood, JM | 1 |
| Bucana, CD; Fidler, IJ; Herbst, RS; Killion, JJ; Knighton, B; Shinohara, H; Wood, J; Yano, S | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Hegyi, I; Hess, C; Pruschy, M; Riesterer, O; Vuong, V; Wood, J | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
4 trial(s) available for vatalanib and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Pyridines | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2011 |
MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Contrast Media; Dextrans; Endothelial Growth Factors; Female; Ferrosoferric Oxide; Gadolinium DTPA; Intercellular Signaling Peptides and Proteins; Iron; Lymphokines; Macromolecular Substances; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mammary Neoplasms, Experimental; Mice; Oxides; Phthalazines; Pyridines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
3 other study(ies) available for vatalanib and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Capillary Permeability; Cell Division; Cell Line; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Humans; Immunohistochemistry; In Situ Hybridization; Lung Neoplasms; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Pleural Effusion, Malignant; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Topics: Adenocarcinoma; Administration, Oral; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Endothelium, Vascular; Enzyme Inhibitors; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Radiotherapy, Adjuvant; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2001 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |